Abstract Introduction Metastatic spine disease (MSD) occurs in up to 40% of cancer patients; advancements in treatment including systemic therapies, radiotherapy, and surgical decompression and stabilization have improved outcomes and extended survival. As a result, the long-term integrity of spine instrumentation is o...
Andrew A. Hardigan, F. Landriel, F. Cofano et al.· Neuro-Oncology Advances· 0 citations
Abstract Introduction As the incidence of metastatic spine disease (MSD) increases, treatments to manage refractory pain, pathologic vertebral body fractures, and spinal cord compression are becoming increasingly common. Given the palliative nature of surgical intervention used to achieve tumor control and thus mitigat...
Andrew A. Hardigan, G. B. Brodano, Christina Griffoni et al.· Neuro-Oncology Advances· 0 citations
Abstract Introduction Given the palliative nature of treatment for metastatic spine disease (MSD), measuring surgical outcomes in this population requires examining comprehensive outcome variables. We sought to achieve an international consensus in how to measure success in the MSD population. Methods The AO Spine Know...
Andrew A. Hardigan, R. de la Garza Ramos, Michael H. Weber et al.· Neuro-Oncology Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
